Mega Genomics (6667) H2 2025 earnings summary

Executive summary

• FY2025 revenue rose 50.5% YoY to RMB247.2m as ancillary products and cancer screening expanded; net profit fell 40.0% to RMB27.0m amid impairment charges and one-off costs.

• Adjusted net profit increased 6.9% to RMB42.0m, excluding impairment changes, trading-resumption expenses, donations and related tax effects.

Financial highlights

• Revenue was RMB247.2m, up 50.5% YoY; gross profit was RMB117.4m, down 1.7%, while cost of sales rose 189.2% to RMB129.8m.

• Net profit was RMB27.0m versus RMB45.0m; profit before tax fell 38.8% to RMB32.8m.

• Adjusted net profit was RMB42.0m versus RMB39.3m, up 6.9%; adjustments included RMB9.5m impairment, RMB5.5m trading-resumption expenses and RMB1.9m donations.

• Cash and cash equivalents declined 15.2% to RMB415.6m at year-end.

Outlook and guidance

• Plans include expanding consumer genetics and cancer screening offerings, increasing R&D investment, strengthening academic and medical partnerships, and developing screening products for additional cancer types.

• Plans for a manufacturing laboratory target broader geographic coverage, shorter reporting cycles and lower operating costs; selective acquisitions may complement the product portfolio and capabilities.

• Two self-developed testing kits received NMPA medical-device registration certificates in 2025; fecal occult blood and transferrin screening products received registration certificates and reached mass production.